Healthcare Triangle, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Healthcare Triangle, Inc. (HCTI) on June 24, 2026. The filing discloses the entry into material definitive agreements regarding the settlement of a prior asset acquisition and the amendment of a share purchase agreement. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics and Capital Structure
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or operating margins. The report focuses on capital structure adjustments and equity issuances:
- Series B Preferred Stock Settlement: Issuance of 2,828,167 shares of common stock to SecureKloud Technologies Ltd. as a "make-whole" settlement for previously issued Series B Preferred Stock that could not be converted due to reverse stock splits.
- Teyame AI Acquisition Amendment: Purchase consideration amended to include $12,000,000 of restricted common stock and 18,000 shares of Series C Convertible Preferred Stock (stated value $1,000 per share).
- Series C Preferred Stock: 23,000 shares designated, ranking senior to common stock but junior to indebtedness. Convertible at the Company's option into 430.21 shares of common stock per preferred share upon shareholder approval.
- Management Earnout: 5,000 shares of Preferred Stock allocated to key management employees, payable over fiscal years 2026 and 2027 based on earnout targets.
Material Changes and Agreements
Two primary material agreements were executed in late June 2026:
- Securities Exchange Agreement with SecureKloud: Resolves a dispute where SecureKloud could not convert Series B Preferred Stock into common stock following two reverse stock splits (aggregate ratio 1:14,940). The Company agreed to issue 2,828,167 Exchange Shares to SecureKloud (or its nominee, Blockedge Technologies Inc.) in exchange for the surrender of the Series B Preferred Stock.
- Amendment No. 1 to Share Purchase Agreement (Teyame AI): Modifies the consideration for the acquisition of Teyame AI. If the issuance of common stock exceeds 19.99% of shares outstanding, the excess will be converted into a pre-funded warrant (PFW) with an exercise price of $0.00001, exercisable only after shareholder approval.
Guidance, Risks, and Contingencies
Conditions Precedent: The closing of the SecureKloud exchange and the conversion of Series C Preferred Stock are contingent upon obtaining stockholder approval as required by Nasdaq Rules 5635(b) and 5635(a), respectively.
Registration Rights: The Company agreed to include the Exchange Shares in its next registration statement for resale under Rule 415.
Risks: The filing includes standard forward-looking statement disclaimers. Actual results may differ due to risks outlined in the Company's Form 10-K filed on April 15, 2026. The Company undertakes no obligation to update forward-looking statements.
Investor Verification Checklist
- Verify the outcome of the required stockholder approvals for the SecureKloud exchange and Series C Preferred Stock conversion.
- Confirm the total number of shares outstanding to determine if the Teyame AI acquisition triggers the 19.99% cap and issuance of pre-funded warrants.
- Review the full text of the Securities Exchange Agreement (Exhibit 10.1) and Amendment No. 1 (Exhibit 10.2) for specific covenants and earnout metrics.
- Monitor the filing of the next registration statement to confirm the inclusion of the 2,828,167 Exchange Shares.
- Assess the impact of the reverse stock splits on the valuation of the original $7.2 million consideration for SecureKloud assets.